SCHEMBL2164274

SCHEMBL2164274

FC(F)(F)Oc1cccc(Nc2nnnc3ccccc23)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 12/20 0.60
EPHX2 P34913 1/20 0.59
RAB9A P51151 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CTDSP1 Q9GZU7 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
SYK P43405 1/20 0.50
CTSC P53634 1/20 0.49
ABCG2 Q9UNQ0 2/20 0.47
DYRK3 O43781 1/20 0.47
MAP4K4 O95819 1/20 0.47
EGFR P00533 1/20 0.47
PDGFRA P16234 1/20 0.47
LTK P29376 1/20 0.47
GRK5 P34947 1/20 0.47
KDR P35968 1/20 0.47
MAPK8 P45983 1/20 0.47
CDK8 P49336 1/20 0.47
CDK7 P50613 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163410 0.85 RAB9A (0.68) PIM1EPHX2RAB9AMEN1KMT2A
SCHEMBL8021016 0.78 MAPT (0.62) EPHX2RAB9ASYKCTSCKDR
SCHEMBL2163041 0.77 PIM1 (0.73) PIM1EPHX2SYKCTSCEGFR
SCHEMBL2163467 0.76 PIM1 (0.56) PIM1ABCG2EGFRKDR
SCHEMBL3757318 0.75 MEN1 (0.69) PIM1RAB9AMEN1KMT2ACTDSP1
SCHEMBL2164209 0.75 EGFR (0.65) RAB9AMEN1KMT2ACTDSP1TDP1
SCHEMBL2165576 0.75 PIM1 (0.57) PIM1MEN1KMT2AABCG2EGFR
SCHEMBL30754724 0.75 SYK (0.63) PIM1EPHX2SYKCTSCEGFR
SCHEMBL14474568 0.75 ABCG2 (0.60) MEN1KMT2ATDP1ABCG2CLK4
SCHEMBL2163065 0.74 PIM1 (0.56) PIM1ABCG2EGFRKDRLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 PIM1 742/4885EPHX2 1549/4885RAB9A 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.